20 miliardi di euro l’anno: i costi per il cancro in Italia – Prevenzione attiva, la vera arma vincente
Chronic inflammation, as a pattern and driver of various pathologies, has been scarcely considered in the past. As a result, technology in this field has not had major developments. Our goal is to move the current technology towards simpler and less expensive methods, compared with the flow cytometry technologies, in order to make the service more accessible and to integrate the CYTOBALANCE results with anamnestic data and the results from the other tests by means of the development of our AI. Then, we will need validation of the AI’s ability to integrate information from CYTOBALANCE, the anamnesis, and the other HELIXAFE tests, to profile an individual based on cancer risk. We also aim at combining CYTOBALANCE with the analysis of other cancer drivers (mitochondrial dysfunction), to further increase the chronic inflammation analysis’ predictive value.
